The Menarini Group

Beijing/Florence – September 09, 2026 -- Gan & Lee Pharmaceuticals (603087.SH) has signed an exclusive licensing agreement with Italy's The Menarini Group for its GLP-1 receptor agonist bofanglutide, a deal worth up to €726 million excluding royalties.

Gan & Lee secures €62 million upfront payment plus milestone potential of €664 million

Under the terms, Gan & Lee will receive a €62 million upfront payment, up to €664 million in milestone payments, and double-digit royalties on net sales across the licensed territory. Menarini will handle regulatory filings and commercialization in 39 countries, covering all 27 European Union member states, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkan nations.

SHERIDAN, WYOMING - April 14, 2026 - Medidata Solutions has received the top "Luminary" placement in Everest Group's 2026 review of life sciences technology platforms, with the assessment citing the company's market performance, partnership portfolio, and AI solution maturity. The recognition arrives alongside two concrete partnership expansions: a deepened agreement with The Menarini Group to deploy Medidata's Study Build AI technology across a global oncology pipeline, and a new integration with CRIO connecting more than 2,500 research sites worldwide. Together, these developments mark a period of deliberate platform consolidation and AI-scale deployment for one of the most broadly deployed clinical data infrastructure providers in the life sciences sector.